Toward a GEP-based PET in myeloma

Abstract

In this issue of Blood, Rasche et al provide the first evidence of the biological basis underlying the occurrence of false-negative scans with use of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in newly diagnosed transplant-eligible multiple myeloma (MM) patients.1